

# Anton W Langerak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3390760/publications.pdf>

Version: 2024-02-01

151  
papers

7,083  
citations

87888

38  
h-index

62596

80  
g-index

155  
all docs

155  
docs citations

155  
times ranked

7856  
citing authors

#	ARTICLE	IF	CITATIONS
1	The miR-200c/141-ZEB2-TGF $\beta$ axis is aberrant in human T-cell prolymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 143-153.	3.5	6
2	Vitreous proteomics, a gateway to improved understanding and stratification of diverse uveitis aetiologies. <i>Acta Ophthalmologica</i> , 2022, 100, 403-413.	1.1	9
3	High-Throughput immunogenetics for precision medicine in cancer. <i>Seminars in Cancer Biology</i> , 2022, 84, 80-88.	9.6	12
4	High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. <i>Blood</i> , 2022, 139, 1557-1563.	1.4	20
5	A novel digital PCR-based method to quantify (switched) B cells reveals the extent of allelic involvement in different recombination processes in the IGH locus. <i>Molecular Immunology</i> , 2022, 145, 109-123.	2.2	3
6	miR-181a is a novel player in the STAT3-mediated survival network of TCR $\alpha\beta$ + CD8+ T large granular lymphocyte leukemia. <i>Leukemia</i> , 2022, 36, 983-993.	7.2	10
7	Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018. <i>Blood Cancer Journal</i> , 2022, 12, 72.	6.2	6
8	Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	0
9	T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Immunology</i> , 2022, 42, 1205-1222.	3.8	2
10	Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. <i>Leukemia</i> , 2022, , .	7.2	3
11	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. <i>Leukemia</i> , 2022, 36, 1961-1968.	7.2	34
12	Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress. <i>Metabolites</i> , 2022, 12, 618.	2.9	16
13	Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. <i>Metabolites</i> , 2022, 12, 619.	2.9	14
14	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
15	Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. <i>Experimental Hematology</i> , 2021, 93, 14-24.	0.4	10
16	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. <i>Leukemia</i> , 2021, 35, 924-928.	7.2	3
17	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, , .	3.3	5
18	Transitioning T-Cell Clonality Testing to High-Throughput Sequencing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 781-783.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 740083.	2.8	5
20	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. <i>Cancers</i> , 2021, 13, 4379.	3.7	17
21	Adult-Onset Autoimmune Enteropathy in an European Tertiary Referral Center. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00387.	2.5	8
22	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. <i>Leukemia Research</i> , 2021, 108, 106652.	0.8	2
23	Multiple Immunoglobulin $\hat{I}$ Gene Rearrangements within a Single Clone Unraveled by Next-Generation Sequencing-Based Clonality Assessment. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1097-1104.	2.8	8
24	Next-Generation Sequencing-Based Clonality Assessment of Ig Gene Rearrangements. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1105-1115.	2.8	25
25	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021, 5, 3188-3198.	5.2	2
26	NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL. <i>Blood</i> , 2021, 138, 1314-1314.	1.4	2
27	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). <i>Blood</i> , 2021, 138, 1548-1548.	1.4	5
28	Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial. <i>Blood</i> , 2021, 138, 1551-1551.	1.4	0
29	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. <i>Frontiers in Oncology</i> , 2021, 11, 780085.	2.8	4
30	Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor- $\hat{I}$ B pathway. <i>Haematologica</i> , 2020, 105, 182-192.	3.5	5
31	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. <i>Journal of Immunology</i> , 2020, 204, 360-374.	0.8	6
32	Validation of a Combined Transcriptome and T Cell Receptor Alpha/Beta (TRA/TRB) Repertoire Assay at the Single Cell Level for Paucicellular Samples. <i>Frontiers in Immunology</i> , 2020, 11, 1999.	4.8	3
33	Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study. <i>British Journal of Haematology</i> , 2020, 190, e201-e204.	2.5	12
34	Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study. <i>Experimental Hematology</i> , 2020, 89, 55-60.e6.	0.4	2
35	Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development. <i>Scientific Reports</i> , 2020, 10, 13814.	3.3	4
36	Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. <i>Leukemia</i> , 2020, 34, 2545-2551.	7.2	29

#	ARTICLE	IF	CITATIONS
37	A very low thymus function identifies patients with substantial increased risk for long-term mortality after kidney transplantation. <i>Immunity and Ageing</i> , 2020, 17, 4.	4.2	15
38	Memento for interprofessional learning. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 755-756.	2.8	1
39	Rapid Low-Cost Microarray-Based Genotyping for Genetic Screening in Primary Immunodeficiency. <i>Frontiers in Immunology</i> , 2020, 11, 614.	4.8	21
40	Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. <i>British Journal of Haematology</i> , 2020, 189, 809-810.	2.5	6
41	Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome. <i>European Cytokine Network</i> , 2020, 31, 154-167.	2.0	9
42	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019, 33, 2241-2253.	7.2	177
43	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
44	The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age. <i>Immunity and Ageing</i> , 2019, 16, 22.	4.2	17
45	Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. <i>Acta Ophthalmologica</i> , 2019, 97, 626-632.	1.1	16
46	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2254-2265.	7.2	70
47	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236.	27.0	599
48	Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2227-2240.	7.2	92
49	PCR GeneScan and Heteroduplex Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes for Clonality Diagnostics in Suspect Lymphoproliferations. <i>Methods in Molecular Biology</i> , 2019, 1956, 77-103.	0.9	6
50	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 269-277.	1.6	250
51	A New and Simple TRG Multiplex PCR Assay for Assessment of Tâ€cell Clonality: A Comparative Study from the EuroClonality Consortium. <i>HemaSphere</i> , 2019, 3, e255.	2.7	9
52	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019, 133, 494-497.	1.4	32
53	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. <i>Blood</i> , 2019, 134, 36-36.	1.4	18
54	Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders. <i>Blood</i> , 2019, 134, 888-888.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD <sup>â€</sup> ) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology, 2019, 37, 7502-7502.	1.6	1
56	Large granular lymphocyte cells and immune dysregulation diseases â€“ the chicken or the egg?. Haematologica, 2018, 103, 193-194.	3.5	5
57	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica, 2018, 103, e158-e161.	3.5	16
58	A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 2018, 131, 955-962.	1.4	61
59	<scp>CD</scp>38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. British Journal of Haematology, 2018, 180, 292-296.	2.5	18
60	Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation. Journal of Visualized Experiments, 2018, , .	0.3	6
61	Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS. Frontiers in Immunology, 2018, 9, 2034.	4.8	10
62	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. Frontiers in Immunology, 2018, 9, 1996.	4.8	8
63	Next-Generation Sequencing Analysis of the Human TCRÎ³Î±+ T-Cell Repertoire Reveals Shifts in VÎ³3- and VÎ±1-Usage in Memory Populations upon Aging. Frontiers in Immunology, 2018, 9, 448.	4.8	31
64	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry Part B - Clinical Cytometry, 2018, 94, 928-934.	1.5	9
65	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 2018, 132, 185-185.	1.4	2
66	High, durable minimal residual disease negativity (MRD <sup>â€</sup> ) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. Journal of Clinical Oncology, 2018, 36, 7508-7508.	1.6	2
67	ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics, 2017, 33, 435-437.	4.1	85
68	Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling. Journal of Immunology, 2017, 198, 3058-3068.	0.8	14
69	Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica, 2017, 102, e57-e60.	3.5	35
70	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. Journal of Immunology, 2017, 198, 3765-3774.	0.8	61
71	T and B Cell Markers in Dried Blood Spots of Neonates with Congenital Cytomegalovirus Infection: B Cell Numbers at Birth Are Associated with Long-Term Outcomes. Journal of Immunology, 2017, 198, 102-109.	0.8	9
72	Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathologica, 2017, 134, 383-401.	7.7	121

#	ARTICLE	IF	CITATIONS
73	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	7.0	27
74	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. <i>Haematologica</i> , 2017, 102, 968-971.	3.5	28
75	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	1.4	108
76	Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 236-243.	2.8	19
77	HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1219825.	4.6	28
78	Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence. <i>Journal of Clinical Immunology</i> , 2017, 37, 133-142.	3.8	13
79	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. <i>Scientific Reports</i> , 2017, 7, 5509.	3.3	44
80	Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus. <i>Frontiers in Immunology</i> , 2017, 8, 32.	4.8	53
81	End-Stage Renal Disease Causes Skewing in the TCR V $\beta$ 2-Repertoire Primarily within CD8+ T Cell Subsets. <i>Frontiers in Immunology</i> , 2017, 8, 1826.	4.8	19
82	Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCR $\beta$ <sup>hi</sup> T cell large granular lymphocyte leukemia. <i>PLoS ONE</i> , 2017, 12, e0175670.	2.5	11
83	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. <i>Oncotarget</i> , 2017, 8, 71981-71995.	1.8	27
84	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. <i>Haematologica</i> , 2016, 101, e369-e373.	3.5	16
85	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	3.5	57
86	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , 2016, 127, 1007-1016.	1.4	130
87	Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 517-526.e3.	2.9	26
88	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	1.4	1
89	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	1.4	70
90	Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?. <i>Journal of Pathology</i> , 2015, 236, 302-314.	4.5	23

#	ARTICLE	IF	CITATIONS
91	End stage renal disease patients have a skewed T cell receptor V $\beta$ 2 repertoire. <i>Immunity and Ageing</i> , 2015, 12, 28.	4.2	20
92	Functional loss of I $\delta$ B1 $\mu$ leads to NF- $\kappa$ B deregulation in aggressive chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2015, 212, 833-843.	8.5	85
93	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. <i>Haematologica</i> , 2015, 100, 315-323.	3.5	38
94	Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6020-7.	7.1	34
95	Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. <i>Haematologica</i> , 2015, 100, 370-376.	3.5	57
96	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015, 126, 1411-1411.	1.4	1
97	A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 720-720.	1.4	2
98	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. <i>Oncotarget</i> , 2015, 6, 42938-42951.	1.8	23
99	The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC). <i>Blood</i> , 2015, 126, 1657-1657.	1.4	0
100	Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials. <i>Blood</i> , 2015, 126, 2924-2924.	1.4	0
101	ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome. <i>Blood</i> , 2015, 126, 1712-1712.	1.4	0
102	Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy. <i>Blood</i> , 2015, 126, 2750-2750.	1.4	1
103	EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player. <i>Blood</i> , 2015, 126, 4126-4126.	1.4	0
104	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. <i>Blood</i> , 2015, 126, 5263-5263.	1.4	0
105	B-cell polymphocytic leukemia: a specific subgroup of mantle cell lymphoma. <i>Blood</i> , 2014, 124, 412-419.	1.4	48
106	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2014, 370, 1101-1110.	27.0	1,284
107	Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1124-1133.e1.	2.9	71
108	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. <i>Lancet Haematology</i> , 2014, 1, e74-e84.	4.6	93

#	ARTICLE	IF	CITATIONS
109	Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. <i>Blood</i> , 2014, 124, 1969-1969.	1.4	0
110	Multicolor Flowcytometric Immunophenotyping Is a Valuable Tool for Detection of Intraocular Lymphoma. <i>Ophthalmology</i> , 2013, 120, 991-996.	5.2	54
111	PCR-Based Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes by GeneScan Analysis or Heteroduplex Analysis for Clonality Assessment in Lymphoma Diagnostics. <i>Methods in Molecular Biology</i> , 2013, 971, 65-91.	0.9	13
112	Successive B-Cell Lymphomas Mostly Reflect Recurrences Rather Than Unrelated Primary Lymphomas. <i>American Journal of Clinical Pathology</i> , 2013, 140, 114-126.	0.7	14
113	Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e67751.	2.5	27
114	Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. <i>Blood</i> , 2012, 119, 4467-4475.	1.4	350
115	Molecular diagnostics in lymphoma: why, when and how to apply. <i>Diagnostic Histopathology</i> , 2012, 18, 53-63.	0.4	6
116	Capillary electrophoresis single-strand conformation analysis (CE-SSCA) for clonality detection in lymphoproliferative disorders. <i>Journal of Hematopathology</i> , 2012, 5, 83-89.	0.4	2
117	The EuroClonality website: information, education and support on clonality testing. <i>Journal of Hematopathology</i> , 2012, 5, 99-103.	0.4	2
118	Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. <i>Journal of Hematopathology</i> , 2012, 5, 35-43.	0.4	33
119	Clonal antigen receptor gene PCR products outside the expected size range. <i>Journal of Hematopathology</i> , 2012, 5, 57-67.	0.4	8
120	PID Comes Full Circle: Applications of V(D)J Recombination Excision Circles in Research, Diagnostics and Newborn Screening of Primary Immunodeficiency Disorders. <i>Frontiers in Immunology</i> , 2011, 2, 12.	4.8	62
121	Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. <i>Blood</i> , 2010, 115, 4770-4777.	1.4	37
122	The Composition of the B Cell Receptor Repertoire In 7428 Cases of Chronic Lymphocytic Leukemia: One Third Stereotyped, Two Thirds Heterogeneous - What Does This Mean?. <i>Blood</i> , 2010, 116, 43-43.	1.4	2
123	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 141-141.	1.4	0
124	Pitfalls in TCR gene clonality testing: teaching cases. <i>Journal of Hematopathology</i> , 2008, 1, 97-109.	0.4	76
125	Generation of T Cells from Human Embryonic Stem Cells.. <i>Blood</i> , 2008, 112, 1527-1527.	1.4	0
126	Immunoglobulin/T-cell receptor clonality diagnostics. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 451-461.	1.6	34



#	ARTICLE	IF	CITATIONS
127	Monoclonal TCR-V $\beta$ 13.1+/CD4+/NKa+/CD8 $\alpha^{\sim}$ /+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. <i>Blood</i> , 2007, 109, 4890-4898.	1.4	72
128	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007, 110, 3112-3121.	1.4	157
129	A New Subtype of T-Cell Acute Leukemia in Very Young Children Is Defined by a Translocation Targeting the C-MYB Oncogene, and a Specific Gene Expression Signature.. <i>Blood</i> , 2007, 110, 982-982.	1.4	0
130	Prognostic Significance of Molecular-Cytogenetic Abnormalities in Pediatric T-ALL Is Not Explained by Immunophenotypic Differences.. <i>Blood</i> , 2007, 110, 4220-4220.	1.4	1
131	T-Cell Receptor V $\alpha$ CDR3 Oligoclonality Frequently Occurs in Childhood Refractory Cytopenia and Severe Aplastic Anemia.. <i>Blood</i> , 2007, 110, 2449-2449.	1.4	2
132	Molecular Monitoring of Lymphoma. , 2006, , 83-109.		1
133	Immunoglobulin and T-cell receptor gene rearrangements. , 2006, , 210-234.		2
134	Recombination in the Human IGK Locus. <i>Critical Reviews in Immunology</i> , 2006, 26, 23-42.	0.5	12
135	New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. <i>Journal of Experimental Medicine</i> , 2005, 201, 1715-1723.	8.5	318
136	BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 495-503.	2.8	85
137	CALM-AF10 and HOX11L2 Abnormalities Define Poor Prognostic Subgroups in Pediatric T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 3279-3279.	1.4	0
138	Unraveling the Consecutive Recombination Events in the Human<i>IGK</i>Locus. <i>Journal of Immunology</i> , 2004, 173, 3878-3888.	0.8	28
139	CALM-AF10 Positive T-ALLs Show a Pattern of Expression Similar to MLL-Translocated Acute Leukemias.. <i>Blood</i> , 2004, 104, 1108-1108.	1.4	1
140	Spectrum of T-large granular lymphocyte lymphoproliferations: ranging from expanded activated effector T cells to T-cell leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 561-562.	2.5	15
141	Molecular immunoglobulin/T- cell receptor clonality analysis in cutaneous lymphoproliferations. Experience with the BIOMED-2 standardized polymerase chain reaction protocol. <i>Haematologica</i> , 2003, 88, 659-70.	3.5	78
142	Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at the IGL locus. <i>Blood</i> , 2001, 97, 1001-1008.	1.4	65
143	Molecular and flow cytometric analysis of the V $\beta$ repertoire for clonality assessment in mature TCR $\beta$ T-cell proliferations. <i>Blood</i> , 2001, 98, 165-173.	1.4	230
144	Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. <i>Blood</i> , 2001, 98, 2456-2465.	1.4	63

#	ARTICLE	IF	CITATIONS
145	Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease. <i>British Journal of Haematology</i> , 2001, 113, 1076-1089.	2.5	5
146	Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia: Proposal for an easy strategy. <i>Medical and Pediatric Oncology</i> , 2001, 36, 352-358.	1.0	32
147	Transcriptional Control of T Lymphocyte Differentiation. <i>Stem Cells</i> , 2001, 19, 165-179.	3.2	68
148	Flow cytometric analysis of the V $\beta$ repertoire in healthy controls. <i>Cytometry</i> , 2000, 40, 336-345.	1.8	174
149	Ig Heavy Chain Gene Rearrangements in T-Cell Acute Lymphoblastic Leukemia Exhibit Predominant Dh6-19 and Dh7-27 Gene Usage, Can Result in Complete V-D-J Rearrangements, and Are Rare in T-Cell Receptor $\alpha$ Chain. <i>Blood</i> , 1999, 93, 4079-4085.	1.4	124
150	Lymphoma with multi-gene rearrangement on the level of immunoglobulin heavy chain, light chain, and T-cell receptor $\beta$ chain. , 1998, 59, 99-100.		11
151	Flow cytometric analysis of the V $\beta$ repertoire in healthy controls. , 0, .		1